Active Treatment | Study | Treatment | Patient Age, yrs (mean) | RA Duration, yrs (mean) | No. Anterior DMARD (mean) | HAQ Score (mean) | RF-positive†, % | CRP, mg/dl (mean) |
---|---|---|---|---|---|---|---|---|
Infliximab | Maini, 199921 | Placebo | 51 | 9 | 3.5 | 1.8 | 77 | 3.0 |
Infliximab | 56 | 8 | 3.8 | 1.8 | 84 | 3.1 | ||
Schiff, 200822 | Placebo | 49 | 8 | — | 1.8 | 77 | 2.7 | |
Infliximab | 49 | 7 | — | 1.7 | 85 | 3.3 | ||
Westhovens, 200623 | Placebo | 52 | 8 | — | 1.5 | 81 | 1.2 | |
Infliximab | 53 | 8 | — | 1.5 | 83 | 1.6 | ||
Zhang, 200624 | Placebo | 49 | 8 | — | — | — | — | |
Infliximab | 47 | 7 | — | — | — | — | ||
Etanercept | Weinblatt, 199925 | Placebo | 53 | 13 | 2.8 | 1.5 | 90 | 2.6 |
Etanercept | 48 | 13 | 2.7 | 1.5 | 84 | 2.2 | ||
Combe, 200626 | Placebo | 53 | 6 | 2.3 | 1.6 | — | 1.2 | |
Etanercept | 51 | 7 | 2.3 | 1.6 | — | 1.2 | ||
Adalimumab | Weinblatt, 200327 | Placebo | 56 | 11 | — | 1.6 | — | 3.1 |
Adalimumab | 57 | 12 | — | 1.6 | — | 2.1 | ||
Keystone, 200428 | Placebo | 56 | 11 | 3.0 | 1.5 | 90 | 1.8 | |
Adalimumab | 56 | 11 | 2.9 | 1.5 | 82 | 1.8 | ||
Kim, 200729 | Placebo | 50 | 7 | 2.4 | 1.3 | 52 | 2.7 | |
Adalimumab | 49 | 7 | 2.4 | 1.4 | 50 | 2.2 | ||
Furst, 200330 | Placebo | 56 | 12 | — | 1.4 | 62 | 1.5 | |
Adalimumab | 55 | 9 | — | 1.4 | 63 | 1.5 | ||
Golimumab | Keystone, 200931 | Placebo | 52 | 7 | — | 1.3 | 81 | 0.8 |
Golimumab | 52 | 5 | — | 1.4 | 87 | 1.0 | ||
Kay, 200832 | Placebo | 35 | 5 | — | 1.3 | — | 2.0 | |
Golimumab | 35 | 6 | — | 1.7 | — | 2.1 | ||
Certolizumab pegol | Keystone, 20085 | Placebo | 52 | 6 | 2.4 | 1.7 | 83 | 1.6 |
Certolizumab pegol | 51 | 6 | 2.3 | 1.7 | 80 | 1.6 | ||
Smolen, 20096 | Placebo | 52 | 6 | 2.2 | 1.6 | 78 | 1.4 | |
Certolizumab pegol | 52 | 6 | 2.2 | 1.6 | 78 | 1.4 | ||
Anakinra | Cohen, 200433 | Placebo | 57 | 10 | — | 1.3 | 78 | 2.6 |
Anakinra | 56 | 11 | — | 1.4 | 76 | 2.7 | ||
Tocilizumab | Genovese, 200834 | Placebo | 54 | 9.8 | 1.6 | 1.5 | — | 2.6 |
Tocilizumab | 53 | 9.8 | 1.6 | 1.5 | — | 2.6 | ||
Smolen, 200835 | Placebo | 51 | 8 | 1.7 | 1.5 | 71 | 2.4 | |
Tocilizumab | 51 | 8 | 1.5 | 1.6 | 83 | 2.6 | ||
Maini, 200636 | Placebo | 51 | 11 | — | — | 96 | 3.2 | |
Tocilizumab | 50 | 11 | — | — | 80 | 2.4 | ||
Kremer, 200937 | Placebo | — | — | — | — | — | — | |
Tocilizumab | — | — | — | — | — | — |
DMARD: disease-modifying antirheumatic drug; CRP: C-reactive protein;
↵† RF-positive: patients positive for rheumatoid factor; HAQ: Health Assessment Questionnaire; RA: rheumatoid arthritis.